Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia

This publication has 6 references indexed in Scilit:

• Purging iron from the heart
  British Journal of Haematology, 2004
• Safety monitoring of cardiac and hepatic systems in β‐thalassemia patients with chelating treatment in Taiwan*
  European Journal of Haematology, 2003
• Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility
  The Lancet, 2003
• Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other Conditions
  Drug Safety, 2003
• Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia
  The Lancet, 2002
• Ultrastructural Pathology of the Heart in Patients with ß-Thalassaemia Major
  Ultrastructural Pathology, 2000